Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
NCT 05919537 Brief Summary This is a phase 1b multi-center, open-label study…
Read more arrow_forwardNCT 05919537 Brief Summary This is a phase 1b multi-center, open-label study…
Read more arrow_forwardNCT 05267626 Brief Summary This is a first in human, open-label, multi-center…
Read more arrow_forwardNCT 04644068 Brief Summary This research is designed to determine if experimental…
Read more arrow_forwardNCT 03947385 Brief Summary This is a Phase 1/2, multi-center, open-label basket…
Read more arrow_forwardNCT 05199753 Brief Summary This is a first-in-human, Phase I/II, open-label, multi-centre,…
Read more arrow_forwardNCT 05176483 Brief Summary This is a multicenter Phase 1b, open label,…
Read more arrow_forwardNCT 03821935 Brief Summary The study will determine the recommended Phase 2…
Read more arrow_forwardNCT 04665206 Brief Summary This is an open-label, dose escalation and expansion…
Read more arrow_forwardNCT 04585750 Brief Summary The Phase 2 monotherapy portion of this…
Read more arrow_forwardNCT 06003621 Brief Summary This phase II study will explore the effect…
Read more arrow_forward